New DNA HIV vaccine shows promise in early safety trial
NCT ID NCT05828095
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a new DNA-based HIV vaccine (INO-6160) alone or with a protein booster in 20 healthy adults without HIV. The main goal was to see if the vaccine is safe and whether it triggers antibodies and T-cells against HIV. The study is complete, and results will help decide if larger trials should move forward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DNA vaccine (INO-6160) and protein booster (VRC HIV Env Trimer 4571 with adjuvant)
What this could lead to
If successful, this could point toward a safe and effective HIV vaccine that triggers strong immune responses.
What could go wrong
This is a very early Phase 1 trial with only 20 participants. It primarily tests safety, not whether the vaccine prevents HIV. Many early vaccine candidates fail to show enough immune response to move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York Blood Center CRS
New York, New York, 10065, United States
-
Penn Prevention CRS
Philadelphia, Pennsylvania, 19104, United States
-
Vanderbuilt Vaccine (VV) CRS
Nashville, Tennessee, 37232, United States